

Vismodegib

Charles M. Rudin

Abstract

Vismodegib (GDC-0449), an orally bioavailable small-molecule inhibitor of Hedgehog signaling, was recently approved by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma that is either metastatic or locally advanced in patients who are not candidates for surgical resection or radiation. Given the absence of previously defined effective drug therapy for this disease, approval was granted primarily on the basis of outcome of a nonrandomized parallel cohort phase II study of 99 patients with advanced basal cell carcinoma, with a primary endpoint of objective response rate. Response rates of 30.3% and 42.9% were observed in metastatic and locally advanced cohorts in this study, respectively, associated with median progression-free survival in both cohorts of 9.5 months. Ongoing clinical investigations include evaluation of the potential efficacy of vismodegib in a variety of diseases and in combination with other agents. The mechanism of action, preclinical and clinical data, and potential utility in other disease contexts are reviewed here. *Clin Cancer Res*; 18(12); 3218–22. ©2012 AACR.

Introduction

Vismodegib is the first targeted inhibitor of the Hedgehog signaling pathway to be approved by the U.S. Food and Drug Administration (FDA). It is also the first agent of any class approved for the treatment of metastatic or locally advanced unresectable basal cell carcinoma (BCC). Its rapid path to market was based, in large part, on the strengths of a non-randomized pivotal phase II study with a primary endpoint of response rate. Data from this study were buttressed by substantial and supportive efficacy, safety, pharmacokinetic, and pharmacodynamic data from other sources. This approval came almost precisely 5 years after the date of the first human administration of vismodegib. The pathway to approval of vismodegib represents an interesting case study in the era of molecularly targeted drug development and shows the willingness of regulatory agencies to consider alternative registration strategies, beyond the traditional randomized phase III study focused on overall survival, in unusual circumstances and in rare disease contexts.

The Hedgehog pathway has been the subject of multiple recent reviews (1) and is outlined schematically in Fig. 1; this *CCR Drug Updates* article focuses primarily on the clinical development of vismodegib, with brief reference to salient details of this particularly interesting signaling cascade.

Author's Affiliation: The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Corresponding Author: Charles M. Rudin, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 544, 1550 Orleans Street, Baltimore, MD 21287. Phone: 410-502-0678; Fax: 410-502-0677; E-mail: rudin@jhmi.edu

doi: 10.1158/1078-0432.CCR-12-0568

©2012 American Association for Cancer Research.

Hedgehog: From Pathway Discovery to Drug

The Hedgehog pathway was initially identified as a critical developmental regulator of embryonic segment polarity in *Drosophila* in 1980 (2). This and related developmental work in fly body patterning was recognized by the Nobel Prize in Physiology or Medicine in 1995. Vertebrate homologs of the *Drosophila* Hedgehog ligand were first reported in 1993, and definition of central components of the mammalian signaling pathway followed in the late 1990s and early 2000s (reviewed in ref. 3). The first definitive linkage of mutation in this pathway to cancer, that is, to development of BCC, was made in 1996 (4, 5).

The first small-molecule inhibitor of the Hedgehog pathway, the naturally occurring compound cyclopamine, was identified in 2000 (6). This discovery, together with rapidly accumulating evidence implicating the Hedgehog pathway in oncogenesis, led to focused efforts by multiple biotechnology and pharmaceutical companies to develop cyclopamine derivatives with improved pharmacologic properties or to develop agents that effectively out-competed cyclopamine for binding to the critical cell-surface activator of Hedgehog signaling, the 7-transmembrane G protein-coupled-like receptor, SMO.

Vismodegib is a member of this second class: structurally unrelated to cyclopamine but able to bind with high affinity and specificity to SMO, leading to potent suppression of Hedgehog signaling in reporter systems and in a preclinical model of Hedgehog-dependent disease (7). An Investigational New Drug application for vismodegib was filed with the FDA in September 2006, leading to launch of a first-in-human phase I clinical trial at 3 U.S. sites in January 2007.




Figure 1. Hedgehog signaling, vismodegib action, and acquired resistance. The Hedgehog pathway is normally regulated through a cascade of primarily inhibitory signals. Any of 3 mammalian Hedgehog (Hh) ligands (Sonic, Indian, or Desert Hedgehog) bind to cell surface PTCH1. Ligand binding to PTCH1 relieves PTCH1 inhibition of the critical activator of Hedgehog signaling, SMO. PTCH1 deficiency, found in the majority of BCC and about 30% of medulloblastoma, is associated with constitutive, ligand-independent activation of SMO. In mammalian cells, derepression of SMO is associated with its translocation from internal vesicles to the cell membrane cilium (not shown). Active SMO signals downstream through an intermediary Sufu, promoting the release of Gli family transcription factors, which can then translocate to the nucleus to affect gene transcription. There are multiple Gli proteins whose functions are somewhat cell type dependent; in general, Gli2 seems to be a particularly strong activator of downstream gene transcription (along with Gli1), while Gli3 is inhibitory in most contexts. Pathway activation and release from Sufu can lead to proteosomal degradation of Gli3 and to preferential nuclear translocation of Gli1 and Gli2, which activate transcription of multiple target genes, including key regulators of the Hedgehog pathway, notably *Gli1* and *PTCH1*. Vismodegib binds to the extracellular domain of SMO, markedly inhibiting downstream signaling, even in the absence of PTCH1. The first documented mechanism of clinical acquired resistance to vismodegib is a secondary mutation in the extracellular domain of SMO, D473H (indicated in the inset as a red circle), which prevents vismodegib binding.

Focused Phase I Development

The first-in-human study of vismodegib employed a traditional 3+3 phase I dose-escalation schema in patients with any advanced solid tumor, designed to define a maximally tolerated dose. We modified this initial plan on the basis of 2 interesting early observations: (i) this agent had strikingly unusual pharmacokinetic properties that obviated the need for continued dose escalation (summarized in the following section); and (ii), this agent had remarkable single-agent activity in a patient with widely metastatic BCC treated in the initial dose cohort.

Hedgehog signaling has been implicated in solid tumor biology through several mechanisms, including a paracrine pathway involving signaling between epithelial cancer cells and surrounding mesenchymal stromal cells (reflecting a common mode of Hedgehog signaling in normal embryonic development), and has a role in

maintenance of a putative tumor stem cell niche through autocrine signaling in a subset of cancer cells with high tumorigenic potential (reviewed in refs. 1, 8). In addition, there are 2 tumor types in which mutations in key regulatory components of the Hedgehog pathway result in markedly hyperactive, constitutive, ligand-independent signaling: BCC and medulloblastoma.

Advanced and surgically incurable BCC can occur spontaneously or in association with an inherited genetic syndrome affecting the Hedgehog pathway, such as basal cell nevus syndrome (BCNS; discussed below; ref. 9). One patient with advanced BCC was included in each of the 3 dose levels explored in phase I. After BCC responses were seen, the trial was amended to include expansion cohorts focusing on patients with advanced BCC. Of the 68 patients ultimately enrolled on this phase I study, 33 had locally advanced or metastatic BCC, and of these 33 patients with

BCC, objective responses were observed in 18 (10). Enrichment of the phase I trial to substantially oversample patients with BCC provided both an important proof of principle about the single-agent efficacy of this novel inhibitor and an immediate framework for the subsequent phase II study supporting registration.

Unusual Pharmacokinetics

Three dose levels were explored in phase I: 150 mg, 270 mg, and 540 mg orally daily (11). Allometric scaling of preclinical animal models suggested estimates of vismodegib half-life in humans as short as 13.6 hours (12), and, in fact, the original phase I study design allowed for consideration of twice-daily dosing. However, single-dose administration followed by 7-day washout in patients revealed minimal decline in plasma drug concentrations between days 2 and 8, suggesting an exceptionally long terminal half-life (13). Vismodegib is highly protein bound, and total drug levels closely parallel blood levels of alpha 1-acid glycoprotein (13). With continuous daily dosing, steady state plasma concentrations averaging 22 $\mu\text{mol/L}$ were achieved within 7 to 14 days, independent of dose: Indistinguishable levels of vismodegib were observed in all 3 dose cohorts (11). On the basis of the observed similar steady state plasma concentrations among initial dose cohorts and the clear signal of biologic efficacy, no further dose escalation was explored. The lowest daily dose level tested, 150 mg, was suggested as the recommended phase II dose.

A subsequent detailed pharmacokinetic study explored the question of whether intermittent dosing could maintain similarly stable and high vismodegib concentrations following an 11-day "loading" period of 150 mg daily (14). However, compared with continuous daily dosing, 3-times-weekly and once-weekly maintenance schedules of vismodegib were associated with 50% and 80% decreases in plasma levels of unbound drug, respectively, below threshold levels most effective in preclinical models, reinforcing the recommended phase II dose and schedule of 150 mg orally daily.

Registration Strategy: Phase II Development in Advanced Basal Cell Carcinoma

On the basis of the observed responses in patients with advanced BCC treated on the phase I protocol and the lack of any standard-of-care therapies in this patient population, a multicenter phase II study was launched to document objective response rate in patients with advanced BCC (15). The phase II study enrolled patients with advanced BCC in 2 cohorts: one with Response Evaluation Criteria in Solid Tumors (RECIST)-measurable metastatic BCC ($n = 33$), and the other with locally advanced BCC considered inoperable or surgically inappropriate ($n = 63$). For the latter cohort, a composite endpoint for objective response that included measurable diameter and ulceration of visible tumors as well as RECIST criteria for localized, but deeply invasive, tumors

was employed. For both cohorts, responses were assessed by centralized independent review.

The primary results of this study largely confirm, and extend, the data obtained in phase I. Objective responses were observed in 30% of patients in metastatic BCC and in 43% of those with locally advanced disease (15). Thirteen patients with locally advanced disease (21%) experienced complete responses. The overall disease control rate (response plus disease stability) for the entire study population was more than 86%. The response rates observed in both cohorts significantly exceeded the predefined criteria for study success and supported the approval of vismodegib in the BCC disease categories defined in this study. However, the long-term durability of these promising effects remains a concern: Median duration of response in both cohorts was 7.6 months, and median progression-free survival 9.5 months (see below, "Acquired Resistance").

Cancer Prevention: Inhibition of Tumor Formation in a High-Risk Cohort

BCNS is caused by germline-inactivating mutation of 1 copy of the *PTCH1* gene, encoding the primary inhibitory regulator of the Hedgehog pathway (Fig. 1). Inactivation of the second allele leads to tumorigenesis. Patients with BCNS commonly develop hundreds to thousands of BCCs over the course of their adult lives (9). A recent small, but innovative, study of 41 patients with BCNS with substantial disease burden evaluated the effect of vismodegib compared with placebo in a 2:1 randomization, with a primary endpoint of reduction in new surgically eligible BCCs (16). Vismodegib significantly reduced the rate of new tumor formation, from 29 to 2.3 tumors per patient per year ($P < 0.001$). In addition, consistent with the larger phase II study above, responses in existing lesions were observed, including some complete regressions. These data suggest that vismodegib may have a role as a cancer-preventive agent, although this study does not definitively distinguish between prevention of tumor initiation and delay in the appearance of clinically significant disease.

Toxicity

The Hedgehog pathway, although playing essential roles in embryonic development, is minimally active in most adult tissues. Nonetheless, adverse events are experienced by patients on vismodegib, particularly with prolonged administration. Several of the most common toxicities seem to be class effects, seen consistently in early-phase clinical studies of structurally diverse SMO inhibitors. Final reports of phase I studies of other SMO antagonists are not yet available, but several have been publicly presented (17–19). Taken together, these data suggest muscle spasms, alopecia, dysgeusia, nausea, and fatigue as common toxicities across the class.

In the phase II BCC registration study of vismodegib, muscle spasms or cramps were experienced by 68% of subjects; alopecia, 64%; dysgeusia, 51%; weight loss, 46%; and fatigue, 36%. Between 20% and 30% of patients

experienced nausea, decreased appetite, or diarrhea. For all of these adverse effects, a large majority reported only grade 1 to 2 (mild to moderate) toxicity. Severe toxicity was rare and without evident consistency or pattern: Only 4 severe adverse events were considered to be possibly related to vismodegib, including 1 patient each with cholestasis, pulmonary embolus, dehydration and/or syncope, and cardiac failure with pneumonia. No deaths on study were attributable to vismodegib.

Although the toxicities of vismodegib are generally mild, the chronic and persistent nature of these toxicities can limit patient willingness to stay on therapy. At the time of data cutoff for the definitive phase II study, 30% of patients with metastatic and 45% of patients with locally advanced BCC had discontinued vismodegib for reasons other than disease progression or death (15); similarly, in the BCNS prevention study, 54% of patients on vismodegib discontinued therapy because of adverse events (16).

Acquired Resistance

Somatic mutations leading to constitutive activation of Hedgehog signaling and consequent dependence on the pathway are found in about a third of medulloblastoma cases. The phase I study of vismodegib included a single patient with widely metastatic *PTCH1*-mutant medulloblastoma, who experienced rapid tumor regression in all sites of disease (20). This dramatic improvement, however, was short lived, followed by multifocal disease progression. Recurrent disease in this individual was associated with an acquired tumor-specific mutation in *SMO* that inhibited vismodegib binding to the protein (Fig. 1, inset; ref. 21).

BCC is a more indolent cancer than medulloblastoma, and the responses observed have been more durable. Nonetheless, the 9.5-month median progression-free survival observed in both patients with locally advanced and with metastatic BCC treated with vismodegib speaks to the need for continued research to define the mechanisms of acquired resistance and to develop combinatorial strategies to improve the long-term prognosis of patients with this disease. A secondary *SMO* mutation has been identified in a progressive lesion from a patient with BCC on vismodegib, suggesting that similar mechanisms of acquired resistance may apply to both BCC and medulloblastoma (unpublished data).

Application in Other Diseases: Combination Therapies

Although BCC is the most common human malignancy, affecting more than 2 million individuals in the United States annually, it is almost always surgically curable: Metastatic BCC is a rare disease. Medulloblastoma, although the most common brain cancer in children, is also not a major cause of cancer mortality. There has been great interest in exploring the potential utility of vismodegib, and other *SMO* inhibitors, in patients with other diseases.

To date, no definitive clinical responses to *SMO* inhibitors have been reported in diseases other than BCC and

medulloblastoma. On the basis of extensive preclinical data implicating Hedgehog signaling in tumor–stroma interactions and in maintenance of tumor progenitor cell populations, several studies have been initiated combining vismodegib with standard cytotoxic therapies or other targeted agents for a wide range of malignancies. Results of most of these studies are not yet available. An initial 199-patient randomized phase II study evaluating first-line cytotoxic therapies for colorectal cancer with vismodegib or placebo was disappointing, with no statistically significant differences in outcome between arms, and a hazard ratio for progression-free survival showing a trend in favor of the control arm (22). Overall survival data for this study are not yet available.

Recent preclinical data strongly support a role for Hedgehog signaling in maintenance of tumorigenic capacity in small cell lung cancer (23). We recently completed accrual to a randomized phase II study evaluating standard first-line chemotherapy for extensive-stage small cell lung cancer alone, with vismodegib, or with another targeted agent (cixutumumab, targeting insulin-like growth factor I receptor), with continuation of the investigational agents as maintenance therapy, through the Eastern Cooperative Oncology Group. Outcome data from this study are not yet available.

Conclusions and Future Directions

Vismodegib is a potent, selective, orally bioavailable Hedgehog antagonist. Its approval represents the latest in a series of success stories in rapid deployment of molecularly targeted anticancer agents, based on a strategy of focusing early-phase clinical development on molecularly defined subsets of patients. Vismodegib shows remarkable activity against BCC, with recent studies supporting both therapeutic and preventive efficacy. Factors contributing to its exceptionally rapid progress from first-in-human testing to regulatory approval include an acceptable toxicity profile, early recognition of achievement of a biologically effective concentration in the first dose cohort explored, and an early-phase development plan that focused on a disease strongly dependent on the pathway being targeted, and for which there was a clear unmet need.

Several questions and challenges remain. Although categorized as mild to moderate, cumulative toxicity of this agent over time has led to discontinuation of therapy in a substantial fraction of patients. Chronic adverse effects will limit the potential utility of vismodegib as a preventive agent in any but the highest risk settings. Strategies to ameliorate some of the common toxicities of vismodegib will be important and may improve the quality of life of patients receiving this, and similar, agents.

The median response duration of 7.6 months in patients with advanced BCC responding to vismodegib underscores the need to consider strategies to treat, or prevent the emergence of, vismodegib-resistant disease. Essentially all Hedgehog inhibitors in clinical development bind the extracellular domain of *SMO*, and cross-resistance is likely.

Notably in this context, although clearly anecdotal, we observed no responses in 7 patients with advanced BCC who had previously progressed on vismodegib when treated with IPI-926, a similarly active SMO inhibitor (19). Agents targeting other critical nodes of the Hedgehog pathway, beyond SMO, are being actively pursued.

Medulloblastoma has peak incidence at age 5, a period of active bone growth and morphogenesis. Exposure of young animals to Hedgehog inhibition has been associated with permanent defects in skeletal development (24). Trials are ongoing to assess the feasibility and efficacy of administration of vismodegib in prepubescent children with this important disease.

Finally, despite multiple lines of preclinical evidence suggesting potential roles for Hedgehog signaling in common lethal cancers, early signals from studies combining

SMO inhibitors with chemotherapy, or following chemotherapy as maintenance, have not yet shown clear evidence of benefit. Multiple such trials are in progress or recently completed, and results are eagerly awaited.

Treating advanced BCC may prove to be the hedgehog's "One Big Thing" (25), even better would be if it turns out to address many things.

Disclosure of Potential Conflicts of Interest

C.M. Rudin has previously been a consultant for Genentech.

Grant Support

Burroughs Wellcome Clinical Scientist Award in Translational Research and the Flight Attendant Medical Research Institute Center of Excellence.

Received March 5, 2012; revised March 13, 2012; accepted March 14, 2012; published OnlineFirst June 7, 2012.

References

- Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. *Nat Rev Cancer* 2011;11:493–501.
- Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in *Drosophila*. *Nature* 1980;287:795–801.
- Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev* 2001;15:3059–87.
- Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell* 1996;85:841–51.
- Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science* 1996;272:1668–71.
- Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. *Nature* 2000;406:1005–9.
- Robarge KD, Brunton SA, Castaneda GM, Cui Y, Dina MS, Goldsmith R, et al. GDC-0449—a potent inhibitor of the hedgehog pathway. *Bioorg Med Chem Lett* 2009;19:5576–81.
- Merchant AA, Matsui W. Targeting Hedgehog—a cancer stem cell pathway. *Clin Cancer Res* 2010;16:3130–40.
- Epstein EH. Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer* 2008;8:743–54.
- Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* 2009;361:1164–72.
- LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. *Clin Cancer Res* 2011;17:2502–11.
- Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. *Xenobiotica* 2009;39:850–61.
- Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. *Clin Cancer Res* 2011;17:2512–20.
- Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. *Clin Cancer Res* 2011;17:5774–82.
- Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med* 2012;366:2171–9.
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med* 2012;366:2180–8.
- Rodon Ahnert J, Baselga J, Tawbi HA, Shou Y, Granvil C, Dey J, et al. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. *J Clin Oncol* 2010;28:2500.
- Siu LL, Papadopoulos K, Alberts SR, Kirchoff-Ross R, Vakkalagadda B, Lang L, et al. A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. *J Clin Oncol* 2010;29:2501.
- Rudin CM, Jimeno A, Miller WH, Eigl BJ, Gettinger SN, Chang ALS, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients with advanced or metastatic solid tumors. *J Clin Oncol* 2011;29:3014.
- Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med* 2009;361:1173–8.
- Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. *Science* 2009;326:572–4.
- Berlin J, Bendell J, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A phase 2, randomized, double-blind, placebo-controlled study of Hedgehog pathway inhibitor GDC-0449 in patients with previously untreated metastatic colorectal cancer. *Ann Oncol* 2010;21:LBA21.
- Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. *Nat Med* 2011;17:1504–8.
- Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. *Cancer Cell* 2008;13:249–60.
- Attributed to Achilochus. *πῶλλ' οἶδ' ἀλώπηξ, ἀλλ' ἔχινος ἔν μέγα* (*The fox knows many things, but the hedgehog knows one big thing*). Circa 650 BCE.